Latest Revenue Growth News

Eneco Refresh Limited has reversed its fortunes with a modest profit in FY25, driven by steady revenue growth and operational improvements across key regions and business units.

DataDot Technology Limited reported a 13% revenue increase and a 56% rise in net profit after tax for FY25, driven by growth in its PropertyVAULT insurance services and new distributor partnerships.

Kinatico Limited has reported a robust 12% increase in revenue and a striking 45% rise in profit after tax for the financial year ended June 2025, underscoring solid operational momentum despite no dividend payouts.

Wagners Holding Company Limited reported a robust FY25 with revenue growth led by construction materials and composite fibre technologies, alongside strategic expansion and debt reduction.

Wagners Holding Company Limited reported a solid FY25 with revenue of $431.3 million, driven by growth in construction materials and composite fibre technologies, while reducing net debt by 29%.

Wagners Holding Company Limited reported a 120% increase in net profit after tax for FY25 despite a 10.4% revenue decline, driven by strong segment performance and cost management. The company also declared a higher fully franked final dividend of 3.2 cents per share.

Iondrive Ltd reported a 94.7% surge in revenue to $1.71 million for FY2025, driven by R&D tax incentives and other income, yet still recorded a net loss of $4.62 million amid high expenses. The company also expanded its footprint in Europe by acquiring a German entity.

Star Combo Pharma has reported a remarkable jump in profit for FY2025, driven by strong revenue growth and a settled insurance claim, while declaring its second dividend and planning production expansion.

Star Combo Pharma Limited reported a 7% increase in total revenue to $27.8 million for FY25, propelled by a 10% rise in its core OEM and Own Brands segment. The company’s profit before tax surged to $5.31 million, reflecting operational strength despite challenges in its Retail division.

Microba Life Sciences reported a 30% increase in revenue to $15.7 million for FY25, driven by strong growth in its core microbiome diagnostic products and successful UK market expansion. Despite narrowing its net loss to $14.9 million, the company is focused on scaling diagnostics adoption and achieving break-even in FY26.

Hazer Group has reported a remarkable FY25 performance with revenues more than doubling and losses slashed by 60%, underpinned by a strategic partnership with KBR and early commercial revenues.

Starpharma reports a significant 183% jump in FY25 revenue to $4.9 million, alongside a 31% reduction in losses and a solid cash position of $15.4 million. The biotech firm’s progress underscores growing momentum in its dendrimer technology pipeline.